• Something wrong with this record ?

The non-antidepressant effects of citalopram: a clinician's perspective

T. Richter, Z. Paluch, S. Alusik,

. 2014 ; 35 (1) : 7-12.

Language English Country Sweden

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc14063687

The authors present an overview of the most often discussed questions concerning citalopram, i.e. its proven effect on the QT interval and related dose reductions. They discuss citalopram's antiplatelet effect including the most recent data and draw attention to serotonin syndrome as its incidence is still underestimated. They go on to discuss hyponatremia pointing out that this condition may develop even in those taking low doses of citalopram. Finally, the authors provide a brief overview of the latest findings on osteoporosis and the serotonergic mechanism inducing it in individuals treated with a selective serotonin reuptake inhibitor.

000      
00000naa a2200000 a 4500
001      
bmc14063687
003      
CZ-PrNML
005      
20140708110847.0
007      
ta
008      
140704s2014 sw f 000 0|eng||
009      
AR
035    __
$a (PubMed)24625921
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Richter, Tomas $u Department of Geriatrics, 1st Faculty of Medicine, Charles University in Prague,, Czech Republic.
245    14
$a The non-antidepressant effects of citalopram: a clinician's perspective / $c T. Richter, Z. Paluch, S. Alusik,
520    9_
$a The authors present an overview of the most often discussed questions concerning citalopram, i.e. its proven effect on the QT interval and related dose reductions. They discuss citalopram's antiplatelet effect including the most recent data and draw attention to serotonin syndrome as its incidence is still underestimated. They go on to discuss hyponatremia pointing out that this condition may develop even in those taking low doses of citalopram. Finally, the authors provide a brief overview of the latest findings on osteoporosis and the serotonergic mechanism inducing it in individuals treated with a selective serotonin reuptake inhibitor.
650    _2
$a citalopram $x aplikace a dávkování $x škodlivé účinky $x farmakologie $7 D015283
650    _2
$a lidé $7 D006801
650    _2
$a hyponatremie $x chemicky indukované $7 D007010
650    _2
$a osteoporóza $x chemicky indukované $7 D010024
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $x škodlivé účinky $x farmakologie $7 D010975
650    _2
$a Romanův-Wardův syndrom $x chemicky indukované $7 D029597
650    _2
$a antagonisté serotoninu $x aplikace a dávkování $x škodlivé účinky $x farmakologie $7 D012702
650    _2
$a serotoninový syndrom $x chemicky indukované $7 D020230
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Paluch, Zoltan $u St. Elizabeth University of Health and Social Work, Bratislava, Slovakia, St. J.N. Neumann Institute, Pribram, Czech Republic.
700    1_
$a Alusik, Stefan $u Institute for Postgraduate Medical Education, Charles University, Prague, Czech Republic. $7 gn_A_00005063
773    0_
$w MED00168352 $t Neuro endocrinology letters $x 0172-780X $g Roč. 35, č. 1 (2014), s. 7-12
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24625921 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140708111137 $b ABA008
999    __
$a ok $b bmc $g 1031171 $s 862419
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 35 $c 1 $d 7-12 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
LZP    __
$a Pubmed-20140704

Find record

Citation metrics

Archiving options